Security
CareDx, Inc. Common Stock · CDNA
CDNANASDAQCommon stockCurrentCIK 1217234Updated Oct 30, 2026
Name history
XDx, Inc. · through Nov 15, 2011EXPRESSION DIAGNOSTICS INC · through Dec 14, 2005
CDNA price & chart
Loading TradingView…
NASDAQ:CDNA on TradingView ↗About the company
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics based information for transplant patients. For more information, please visit www.caredx.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
CareDx raises 2026 revenue outlook to $520M-$530M as it plans AlloHeme launch in Q1 2027 ↗
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
CareDx, Inc. files 8-K/A ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Completion of Acquisition or Disposition of Assets
Items 2.01, 9.01
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 432,307,000Source | 476,985,000Source | 532,988,000Source | 444,257,000Source | 466,777,000Source | 411,062,000Source | 489,638,000Source | 452,406,000Source | 413,228,000Source | 491,050,000Source | 466,826,000Source | 542,991,000Source |
| Property, Plant and Equipment, NetUSD | 30,845,000Source | 34,015,000Source | 26,838,000Source | 31,934,000Source | 34,202,000Source | 33,156,000Source | 32,729,000Source | 34,411,000Source | 32,971,000Source | 33,552,000Source | 35,246,000Source | 35,529,000Source |
| GoodwillUSD | 40,336,000Source | 40,336,000Source | 35,968,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 37,523,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 33,446,000Source | 40,361,000Source | 18,556,000Source | 36,037,000Source | 41,896,000Source | 32,102,000Source | 37,247,000Source | 43,330,000Source | 31,960,000Source | 38,184,000Source | 45,701,000Source | 43,051,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 91,435,000Source | 95,400,000Source | 373,636,000Source | 68,212,000Source | 95,782,000Source | 77,923,000Source | 88,745,000Source | 93,299,000Source | 65,429,000Source | 114,689,000Source | 82,197,000Source | 89,921,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 47,844,000Source | 66,627,000Source | 34,377,000Source | 67,362,000Source | 66,161,000Source | 44,585,000Source | 71,485,000Source | 60,149,000Source | 42,628,000Source | 64,605,000Source | 51,061,000Source | 66,312,000Source |
| Inventory, NetUSD | 28,328,000Source | 19,263,000Source | 6,982,000Source | 27,915,000Source | 19,234,000Source | 26,404,000Source | 22,929,000Source | 20,130,000Source | 26,705,000Source | 19,503,000Source | 19,471,000Source | 19,232,000Source |
| Assets, CurrentUSD | 300,280,000Source | 334,087,000Source | 429,223,000Source | 307,296,000Source | 320,609,000Source | 269,395,000Source | 350,239,000Source | 303,095,000Source | 257,132,000Source | 351,832,000Source | 313,713,000Source | 387,849,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 29,891,000Source | 7,344,000Source | 14,228,000Source | 25,764,000Source | 6,343,000Source | 11,230,000Source | 24,908,000Source | 6,895,000Source | 10,591,000Source | 7,071,000Source | 7,763,000Source | 9,216,000Source |
| Operating Lease, Right-of-Use AssetUSD | 24,047,000Source | 25,823,000Source | 16,203,000Source | 25,372,000Source | 27,188,000Source | 21,206,000Source | 26,390,000Source | 28,591,000Source | 22,760,000Source | 24,340,000Source | 29,891,000Source | 34,689,000Source |
| Other Assets, NoncurrentUSD | 2,802,000Source | 1,771,000Source | 5,679,000Source | 2,731,000Source | 1,958,000Source | 3,415,000Source | 2,147,000Source | 2,060,000Source | 3,353,000Source | 2,221,000Source | 1,353,000Source | 3,828,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 121,167,000Source | 203,739,000Source | 107,390,000Source | 116,887,000Source | 202,108,000Source | 97,527,000Source | 110,289,000Source | 196,181,000Source | 110,127,000Source | 112,617,000Source | 205,498,000Source | 112,080,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 51,000Source | 50,000Source | 51,000Source | 53,000Source | 50,000Source | 51,000Source | 51,000Source | 49,000Source | 50,000Source | 51,000Source | 49,000Source | 52,000Source |
| Retained Earnings (Accumulated Deficit)USD | -719,047,000Source | -704,252,000Source | -505,446,000Source | -695,161,000Source | -696,844,000Source | -732,550,000Source | -636,595,000Source | -695,450,000Source | -735,359,000Source | -626,242,000Source | -678,269,000Source | -460,444,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,955,000Source | -7,179,000Source | 0Source | -6,113,000Source | -7,964,000Source | -6,272,000Source | -7,089,000Source | -8,108,000Source | -5,515,000Source | -8,569,000Source | -6,963,000Source | -7,503,000Source |
| Stockholders' Equity Attributable to ParentUSD | 311,140,000Source | 273,246,000Source | 425,598,000Source | 327,370,000Source | 264,669,000Source | 313,535,000Source | 379,349,000Source | 256,225,000Source | 303,101,000Source | 378,433,000Source | 261,328,000Source | 430,911,000Source |
| Additional Paid in Capital, Common StockUSD | 1,036,091,000Source | 984,627,000Source | 930,993,000Source | 1,028,591,000Source | 969,427,000Source | 1,052,306,000Source | 1,022,982,000Source | 959,734,000Source | 1,043,925,000Source | 1,013,193,000Source | 946,511,000Source | 898,806,000Source |
| Liabilities and EquityUSD | 432,307,000Source | 476,985,000Source | 532,988,000Source | 444,257,000Source | 466,777,000Source | 411,062,000Source | 489,638,000Source | 452,406,000Source | 413,228,000Source | 491,050,000Source | 466,826,000Source | 542,991,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 99,044,000Source | 81,440,000Source | 93,698,000Source | 93,180,000Source | 78,331,000Source | 79,153,000Source | 85,284,000Source | 70,211,000Source | 89,849,000Source | 89,371,000Source | 78,072,000Source | 75,975,000Source |
| Operating Lease, Liability, CurrentUSD | 6,432,000Source | 6,124,000Source | 6,047,000Source | 6,342,000Source | 6,062,000Source | 6,661,000Source | 6,205,000Source | 6,054,000Source | 6,515,000Source | 6,103,000Source | 5,943,000Source | 5,591,000Source |
| Accounts Payable, CurrentUSD | 11,597,000Source | 6,239,000Source | 9,493,000Source | 9,863,000Source | 5,874,000Source | 9,066,000Source | 8,072,000Source | 9,976,000Source | 9,988,000Source | 7,686,000Source | 12,872,000Source | 9,942,000Source |
| Operating Lease, Liability, NoncurrentUSD | 21,212,000Source | 23,841,000Source | 13,200,000Source | 22,780,000Source | 25,386,000Source | 17,837,000Source | 24,072,000Source | 26,893,000Source | 19,679,000Source | 22,263,000Source | 28,278,000Source | 33,406,000Source |
| Deferred Income Tax Liabilities, NetUSD | 117,000Source | 202,000Source | 86,000Source | 131,000Source | 50,000Source | 130,000Source | 129,000Source | 43,000Source | 181,000Source | 164,000Source | 136,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | 634,000Source | 96,946,000Source | 406,000Source | 636,000Source | 96,721,000Source | 407,000Source | 644,000Source | 97,686,000Source | 257,000Source | 645,000Source | 96,551,000Source | 249,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 240,900,000Source | — | — | 228,900,000Source | — | — | 215,900,000Source | — | — | 235,400,000Source | 293,100,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 181,000Source | 164,000Source | 136,000Source | — |
| Long-term Debt | — | —Source | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,899,000Source | 3,600,000Source | 15,018,000Source | 14,194,000Source | 14,386,000Source | 11,595,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,803,000Source | 8,931,000Source | 34,864,000Source | 66,406,000Source | 49,086,000Source | 46,553,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,078,000Source | 6,640,000Source | -22,521,000Source | 13,741,000Source | -16,016,000Source | 6,660,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 346,000Source | 2,674,000Source | 4,959,000Source | 1,018,000Source | -54,000Source | 2,859,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -149,000Source | 101,000Source | 72,000Source | -278,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 4,333,000Source | -26,584,000Source | 42,032,000Source | 38,048,000Source | -18,388,000Source | -25,239,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 6,682,000Source | 610,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 11,059,000Source | 1,325,000Source | 2,158,000Source | -483,000Source | 40,446,000Source | -228,502,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 2,511,000Source | 3,065,000Source | 12,121,000Source | 10,092,000Source | 3,059,000Source | 5,933,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 0Source | 87,768,000Source | 522,000Source | 27,541,000Source | 642,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,911,000Source | -643,000Source | -93,394,000Source | -5,606,000Source | -29,606,000Source | -4,535,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 12,494,000Source | -25,979,000Source | -49,294,000Source | 32,491,000Source | -7,660,000Source | -258,253,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 91,986,000Source | 95,992,000Source | 374,157,000Source | 68,763,000Source | 78,474,000Source | 89,295,000Source | 65,980,000Source | 115,274,000Source | 82,783,000Source | 90,443,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 8,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 284,000Source | 317,000Source | 738,000Source | 392,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 100,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 8,418,000Source | 16,923,000Source | 10,654,000Source | 9,424,000Source | 9,803,000Source | 8,931,000Source | 34,864,000Source | 66,406,000Source | 49,086,000Source | 46,553,000Source |
| Amortization of Intangible AssetsUSD | — | — | 1,602,000Source | 1,552,000Source | 529,000Source | 1,589,000Source | 1,618,000Source | 1,539,000Source | 6,351,000Source | 6,346,000Source | 6,467,000Source | 6,229,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 240,900,000Source | — | — | — | — | — | — | 235,400,000Source | 293,100,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 8,700,000Source | 7,800,000Source | 7,900,000Source | 5,200,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 1,500,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | -119,000Source | 0Source | -48,000Source | -91,000Source | -44,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,109,000Source | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 0Source | 0Source | 0Source | -350,000Source | -600,000Source | -5,360,000Source | -5,710,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 28,429,000Source | 31,744,000Source | 40,908,000Source | 27,683,000Source | 30,484,000Source | 22,769,000Source | 107,565,000Source | 123,784,000Source | 117,868,000Source | 100,397,000Source |
| GoodwillUSD | — | — | 40,336,000Source | 40,336,000Source | 35,968,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 40,336,000Source | 37,523,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | 0Source | 1,700,000Source | 0Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | -15,000Source | 200,000Source | 3,882,000Source | -117,000Source | -32,012Source | 58,000Source | 271,000Source | 310,000Source | 141,000Source | 379,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -1,181,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,675,000Source | -10,637,000Source | 110,636,000Source | -8,568,000Source | 2,809,000Source | -10,353,000Source | -21,354,000Source | 52,549,000Source | -190,284,000Source | -76,613,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 1,675,000Source | -10,637,000Source | 110,636,000Source | -8,568,000Source | 2,809,000Source | -10,353,000Source | -21,354,000Source | 52,549,000Source | -190,284,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 1,906,000Source | 3,284,000Source | 1,295,000Source | 2,436,000Source | 1,579,000Source | 3,079,000Source | 9,698,000Source | 12,094,000Source | 13,220,000Source | 997,000Source |
| Operating ExpensesUSD | — | — | 100,301,000Source | 96,604,000Source | 18,725,000Source | 97,800,000Source | 116,502,000Source | 98,059,000Source | 410,586,000Source | 293,020,000Source | 483,687,000Source | 399,024,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -107,000Source | 283,000Source | -440,000Source | 72,000Source | -330,000Source | 295,000Source | 524,000Source | 329,000Source | 1,343,000Source | -2,872,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 109,000Source | 3,049,000Source | 5,723,000Source | 8,936,000Source | 120,000Source | 2,435,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 0Source | — | — | — | — | — | — | 10,000Source | 107,000Source |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | — | — | — | — | — | — | — |
| Payments to Acquire Property, Plant, and Equipment | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 100,055,000Source | 82,883,000Source | 131,948,000Source | 86,679,000Source | 117,700,000Source | 84,685,000Source | 379,805,000Source | 333,785,000Source | 280,324,000Source | 321,793,000Source |
| Operating Income (Loss)USD | — | — | -246,000Source | -13,721,000Source | 113,223,000Source | -11,121,000Source | 1,198,000Source | -13,374,000Source | -30,781,000Source | 40,765,000Source | -203,363,000Source | -77,231,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -107,000Source | 283,000Source | -440,000Source | 72,000Source | -330,000Source | 295,000Source | 524,000Source | 329,000Source | 1,343,000Source | -2,872,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 1,660,000Source | -10,437,000Source | 114,518,000Source | -8,685,000Source | 2,777,000Source | -10,295,000Source | -21,083,000Source | 52,859,000Source | -190,143,000Source | -76,234,000Source |
| Income Tax Expense (Benefit)USD | — | — | -15,000Source | 200,000Source | 3,882,000Source | -117,000Source | -32,012Source | 58,000Source | 271,000Source | 310,000Source | 141,000Source | 379,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,675,000Source | -10,637,000Source | 110,636,000Source | -8,568,000Source | 2,809,000Source | -10,353,000Source | -21,354,000Source | 52,549,000Source | -190,284,000Source | -76,613,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.03Source | -0.2Source | 2.15Source | -0.16Source | 0.05Source | -0.19Source | -0.4Source | 1Source | -3.54Source | -1.44Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | -0.2Source | 2.07Source | -0.16Source | 0.05Source | -0.19Source | -0.4Source | 0.93Source | -3.54Source | -1.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 52,507,582Source | 52,903,338Source | 51,469,375Source | 54,304,754Source | 51,151,794Source | 55,262,459Source | 53,287,546Source | 52,773,247Source | 53,764,705Source | 53,321,625Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 53,736,790Source | 52,903,338Source | 53,422,523Source | 54,304,754Source | 53,129,928Source | 55,262,459Source | 53,287,546Source | 56,620,590Source | 53,764,705Source | 53,321,625Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 1,602,000Source | 1,552,000Source | 529,000Source | 1,589,000Source | 1,618,000Source | 1,539,000Source | 6,351,000Source | 6,346,000Source | 6,467,000Source | 6,229,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 420,000Source | 209,000Source | 69,000Source | 657,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | — | 11,595,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,109,000Source | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 0Source | 0Source | 0Source | -350,000Source | -600,000Source | -5,360,000Source | -5,710,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 28,429,000Source | 31,744,000Source | 40,908,000Source | 27,683,000Source | 30,484,000Source | 22,769,000Source | 107,565,000Source | 123,784,000Source | 117,868,000Source | 100,397,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,128,000Source | 55,151,000Source | -188,421,000Source | -73,089,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,013,000Source | 3,001,000Source | 1,735,000Source | 2,364,000Source | 1,909,000Source | 2,784,000Source | 9,174,000Source | 11,765,000Source | 11,867,000Source | 3,762,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 1,675,000Source | -10,637,000Source | 110,636,000Source | -8,568,000Source | 2,809,000Source | -10,353,000Source | -21,354,000Source | 52,549,000Source | -190,284,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 1,906,000Source | 3,284,000Source | 1,295,000Source | 2,436,000Source | 1,579,000Source | 3,079,000Source | 9,698,000Source | 12,094,000Source | 13,220,000Source | 997,000Source |
| Operating ExpensesUSD | — | — | 100,301,000Source | 96,604,000Source | 18,725,000Source | 97,800,000Source | 116,502,000Source | 98,059,000Source | 410,586,000Source | 293,020,000Source | 483,687,000Source | 399,024,000Source |
| Research and Development ExpenseUSD | — | — | 16,769,000Source | 17,486,000Source | 22,376,000Source | 16,830,000Source | 21,416,000Source | 18,524,000Source | 71,429,000Source | 72,405,000Source | 81,866,000Source | 90,388,000Source |
| Selling and Marketing ExpenseUSD | — | — | 24,449,000Source | 19,802,000Source | 33,441,000Source | 24,279,000Source | 30,373,000Source | 22,991,000Source | 102,643,000Source | 81,718,000Source | 83,334,000Source | 96,027,000Source |
Offerings
Registration 333-295388
Filing attachments
tm2612370d2_ex4-2.htm · S-3ASR · 2026-04-28
Exhibit 4.2 CAREDX, INC. And , as Trustee INDENTURE Dated as of, TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION …
Read attachment ↗tm2612370d2_ex4-3.htm · S-3ASR · 2026-04-28
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CAREDX, INC. [IF APPLICABLE, INSERT - FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % AND THE ISSUE DATE IS ] [IF THE SECURITY IS A GLOBAL SECURITY, INSERT - THIS NOTE…
Read attachment ↗tm2611749d3_ex99-1.htm · 8-K · 2026-04-28
EX-99.1 3 tm2611749d3_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CareDx Announces First Quarter 2026 Financial Results First Quarter Revenue Growth of 39% Driven by Strong Performance Across Testing Services and Patient and Digital Solutions Raises 2026 Revenue Guidance to $447 Million to $465 Million and Raises 2026 AEBITDA Guidance to $43 Million to $57 Million BRISBANE, Calif. - (BUSINESS WIRE) - CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™, a leading precision medicine company foc…
Read attachment ↗tm2611749d3_ex99-2.htm · 8-K · 2026-04-28
EX-99.2 4 tm2611749d3_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing Transaction extends CareDx’s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx’s FY2026 Adju…
Read attachment ↗tm2611749d1_ex99-1.htm · 8-K · 2026-04-16
EX-99.1 3 tm2611749d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Apr 15, 2026 4:30 PM Eastern Daylight Time CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results Transaction Expected to Sharpen CareDx’s Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA Margin Expansion Expects First …
Read attachment ↗d936250dex991.htm · 8-K · 2025-06-03
EX-99.1 2 d936250dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CareDx Announces Repurchase of 5% of Outstanding Shares Board of Directors Authorizes New $50 Million Share Repurchase Program BRISBANE, Calif. - CareDx, Inc. (Nasdaq: CDNA), - The Transplant Company™ - a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has comp…
Read attachment ↗